Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cytotechnology is Scopus-indexed (Q3, CiteScore 2.3), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer.
Checked against the index lists dated .
ISSN 0920-9069Verify ISSN ↗1573-0778Verify ISSN ↗
Publisher: Springer
Cost to publish: About US$4,190 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biotechnology | 220 / 325 | 32nd | Q3 |
| Biomedical Engineering | 237 / 342 | 30th | Q3 |
| Clinical Biochemistry | 94 / 124 | 24th | Q4 |
| Bioengineering | 137 / 168 | 18th | Q4 |
| Cell Biology | 254 / 289 | 12th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1987–present, best quartile Q3, CiteScore 2.3.
Cytotechnology is Q3 in Biotechnology (rank 220 of 325), Q3 in Biomedical Engineering (rank 237 of 342) and Q4 in Clinical Biochemistry (rank 94 of 124), by CiteScore 2025. It is ranked in 5 subject areas in all.
Cytotechnology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.3, which places it in quartile Q3 at the 32nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.534, quartile Q3, with an H-index of 83.
The publisher lists an article processing charge of about US$4,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cytotechnology is published by Springer. Its print ISSN is 0920-9069 and its online ISSN is 1573-0778.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cytotechnology has an h-index of 94 and a 2-year mean of 1.51 citations per paper (OpenAlex). Its Scopus CiteScore is 2.3, quartile Q3. On 2-year citations it ranks #206 of 309 Scopus journals in Biotechnology.
Cytotechnology published 188 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2026), authors are most often from China (68.5%), India (6.2%) and Türkiye (5.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (2.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.